Allogene Therapeutics

ICYMI: Katie Couric offered a powerful look at where #CART may be headed next - including off-the-shelf approaches and MRD testing being studied to reduce wait time, expand access, and bring care closer to home for people with #LBCL. #celltherapy #allogeneic Read More: https://lnkd.in/gg8x5yhR

Another important milestone – and further momentum for cema-cel. We are pleased to announce that the FDA has granted RMAT and Fast Track designations to our investigational, off-the-shelf #allogeneic #CART product for the treatment of #LBCL. #celltherapy Learn more: https://lnkd.in/ehhZeCt9

Experience the allogeneic advantage. Allogene’s investigational AlloCAR T products aim to redefine the #CART landscape by addressing the key limitations of autologous treatments – offering the potential for greater speed, scalability, and access for patients. #celltherapy #allogeneic Discover the Allogeneic Advantage: Allogene.com/Home

We aim to redefine #autoimmune disease treatment with ALLO-329, an investigational allogeneic #CART powered by Dagger® technology, which is designed to reduce or eliminate lymphodepletion. #celltherapy #allogeneic Uncover the Potential of ALLO-329: Allogene.com/Pipeline

As CAR T makes promising strides into solid tumors – including new findings in metastatic RCC – Arie Belldegrun, MD will join #KCRS26 for a fireside chat on innovation, investment and the future of kidney cancer research.   Learn more about: https://lnkd.in/gJHau7HS

Allogene is advancing ALLO-329 – an investigational “off-the-shelf” AlloCAR T product for autoimmune disease, powered by our proprietary Dagger® technology. See how we’re aiming to reset the immune system, expand access and transform care. #autoimmune #CART #celltherapy #allogeneic Uncover the Potential of ALLO-329: Allogene.com/Pipeline

For years, the field has asked whether #CART can make a meaningful impact in solid tumors. Phase 1 TRAVERSE data for ALLO-316, now published in JCO Journals, offer an important proof point: durable responses in heavily pretreated metastatic kidney cancer and support for the potential of allogeneic #CART in solid tumors. #celltherapy #allogeneic Learn More: https://lnkd.in/gxgjV3PN

A new CEO. A fresh set of ideas. And Chapter 2 is just beginning. Great article by Ron Leuty San Francisco Business Times Read more: https://lnkd.in/gu86tnks

A new 1L consolidation approach is being studied to help predict and potentially prevent relapse in LBCL patients following frontline therapy. Learn more about the ALPHA3 clinical trial and its potential to revolutionize patient care. #LBCL #CART #celltherapy #allogeneic Learn More About ALPHA3: https://lnkd.in/eT8WT9Ar

1 in 3 LBCL patients will see their cancer return after 1L treatment. Discover how the ALPHA3 trial design combines investigational minimal residual disease (MRD) testing technology and an off-the-shelf CAR T product to intervene early and potentially improve cure rates. #LBCL #CART #allogeneic #celltherapy Learn More About ALPHA3: https://lnkd.in/eT8WT9Ar